(NASDAQ: ORGO) Organogenesis Holdings's forecast annual revenue growth rate of 0.04% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 5.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.01%.
Organogenesis Holdings's revenue in 2024 is $448,392,000.On average, 1 Wall Street analysts forecast ORGO's revenue for 2024 to be $60,415,886,736, with the lowest ORGO revenue forecast at $60,415,886,736, and the highest ORGO revenue forecast at $60,415,886,736. On average, 1 Wall Street analysts forecast ORGO's revenue for 2025 to be $58,841,160,863, with the lowest ORGO revenue forecast at $58,841,160,863, and the highest ORGO revenue forecast at $58,841,160,863.
In 2026, ORGO is forecast to generate $59,218,734,468 in revenue, with the lowest revenue forecast at $59,218,734,468 and the highest revenue forecast at $59,218,734,468.